Back to search
Search Results 1-10 of 48 clinical trials found.
Reduction of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop
medications has been shown to be effective in delaying or preventing the progression of
glaucoma, and it is the only proven method for reducing the risk of glaucomatous visual field
This study is being conducted to determine how well DE-126 ophthalmic solution works
(efficacy) in safely lowering IOP when dosed as topical eyedrops. This study will evaluate
the safety and efficacy of DE-126, ophthalmic solution in subjects with Primary Open Angle
Glaucoma (POAG) or Ocular Hypertension (OHT).
The IOP will be measured at 3 different times throughout the day, over 4 total visits during
a 3-month treatment period (with up to 4 extra weeks observation if the patient must stop
taking current eye drops to lower IOP). Safety assessments will be done throughout the study,
including ocular signs and symptoms, and vital ...
This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled
study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
In this study researchers want to learn more about changes in visual acuity (clarity of
vision) with a high dose treatment with Aflibercept (Eylea) in patients suffering from
neovascular age-related macular degeneration (nAMD). Neovascular AMD is an eye disease that
causes blurred vision or a blind spot due to abnormal blood vessels that leak fluid or blood
into the light sensitive lining inside the eye (retina). The fluid buildup causes the central
part of the retina (macula) responsible for sharp, straight-ahead vision to swell and thicken
(edema), which distorts vision.
This prospective, concurrent controlled, open-label, multicenter study is designed to collect
additional safety data through 5 years of follow-up for subjects randomized to either the
treatment arm (PRESERFLO® MicroShunt with MMC) or the control arm (Trabeculectomy with MMC)
of the INN-005 clinical study.
This is a prospective, multicenter, single-arm, open-label clinical study of the commercially
available TECNIS Toric II IOL. The study will be conducted in up to 192 subjects needing
unilateral or bilateral cataract surgery in up to 8 sites in United States (US). The subjects
will be followed for up to 3-months postoperatively.
Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy
(DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety
of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator Arm
The objectives of this study are to evaluate the safety and efficacy of Zimura intravitreal
administration in patients with geographic atrophy secondary to age-related macular
Back to search
Learn more about myUCLAhealth